Surefire Medical's Groundbreaking COSY Clinical Trial Results Presented at ECIO: Is Coiling Prior to Radioembolization Still Necessary in Minimally Invasive Treatment of Liver Cancer? Results: Fluoroscopy time reduced by 70%; Procedure Time, Contrast Dose Cut 50%
WESTMINSTER, Colo., April 23, 2014 /PRNewswire/ -- Surefire Medical, Inc. announced that a symposium focused on the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial will be held during the European Conference on Interventional Oncology (ECIO) meeting taking place in Berlin, Germany April 23-26. The randomized, prospective radioembolization study showed significant reductions in fluoroscopy time, procedure time, radiation dose and contrast dose when using the technologically advanced Surefire Infusion System without coiling.
"This important study confirmed the feasibility and benefits of performing Selective Internal Radiation Therapy (SIRT) without the need to place permanent coils," said Prof. Tobias Jakobs, M.D. of Krankenhaus Barmherzige Brueder in Munich, Germany, who is moderating the symposium on technological advances impacting the treatment of hepatocellular carcinoma (HCC) and liver metastases (SY 1702). "We are continually looking for high quality clinical data showing that cutting-edge devices like the Surefire Infusion System enable more efficient and cost-effective treatments to improve our patients' outcomes."
Aravind Arepally, M.D., Chief Scientific Officer and Chairman of Surefire's Scientific Advisory Board, will discuss the implications for clinical practice of the study findings:
- Procedure time reduced by >50 percent
- Radiation dose to both patient and physician cut in half
- Fluoroscopy time decreased by 70 percent
- Contrast dose reduced by 50 percent
- Use of the Surefire Infusion System without coiling found safe, with no minor or major adverse events at 30-day follow-up
SIRT, a direct-to-tumor minimally invasive radiation therapy, is generally used to treat selected patients with primary or secondary liver tumors.
The Surefire Infusion System is a first-in-class medical device with a unique expandable tip designed to minimize reflux and maximize direct-to-tumor delivery of cancer-fighting agents. It is used for diagnostic and therapeutic radioembolization or chemoembolization procedures.
About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire's infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. The Surefire Infusion Systems have received regulatory approval in the U.S., Europe, Canada, Australia, New Zealand and Taiwan. www.surefiremedical.com
SOURCE Surefire Medical